Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.53 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | TNKS | O95271 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31285855 | 1.00 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2OPRM1HSD11B1MEN1 | |
| SCHEMBL607235 | 0.90 | OPRM1 (0.53) | ALDH1A1SMN1; SMN2OPRM1HSD11B1CTSS | |
| SCHEMBL7191677 | 0.88 | ALDH1A1 (0.61) | ALDH1A1SMN1; SMN2OPRM1HSD11B1MEN1 | |
| SCHEMBL7179611 | 0.86 | ALDH1A1 (0.62) | ALDH1A1SMN1; SMN2OPRM1HSD11B1MEN1 | |
| SCHEMBL7185917 | 0.86 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2OPRM1HSD11B1MEN1 | |
| SCHEMBL7179604 | 0.86 | ALDH1A1 (0.62) | ALDH1A1SMN1; SMN2OPRM1HSD11B1MEN1 | |
| SCHEMBL11851923 | 0.85 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2OPRM1HSD11B1MEN1 | |
| SCHEMBL14515170 | 0.85 | OPRM1 (0.60) | ALDH1A1SMN1; SMN2OPRM1HSD11B1MEN1 | |
| SCHEMBL11840422 | 0.83 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2OPRM1HSD11B1MEN1 | |
| SCHEMBL30825655 | 0.82 | OPRM1 (0.57) | OPRM1HSD11B1CYP1A2CYP2C9SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111848598-A | Heterocyclic ring-containing compound, application thereof and composition containing heterocyclic ring-containing compound | 健艾仕生物医药有限公司 | 2020-10-30 | — | — | CN | disclosed |
| WO-2020216378-A1 | HETEROCYCLIC COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME | 健艾仕生物医药有限公司 | 2020-10-29 | — | — | WO | disclosed |
| US-9505749-B2 | Quinazolinone compounds and derivatives thereof | AMGEN INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20150225396-A1 | Quinazolinone Compounds and Derivatives Thereof | AMGEN INC. | 2015-08-13 | — | — | US | disclosed |
| EP-2890696-A1 | QUINAZOLINONE COMPOUNDS AND DERIVATIVES THEREOF | AMGEN, INC. (US) | 2015-07-08 | — | — | EP | disclosed |
| CN-104211712-A | Artemisinin derivative containing heteroaryl piperidine, preparation method and application thereof | SHANGHAI INST MATERIA MEDICA | 2014-12-17 | — | — | CN | disclosed |
| WO-2014036022-A1 | QUINAZOLINONE COMPOUNDS AND DERIVATIVES THEREOF | AMGEN INC. (US) | 2014-03-06 | — | — | WO | disclosed |
| US-7879880-B2 | such as [4-[(2-aminopyridin-4-yl)methyl]piperazin-1-yl]-[4-(pyridin-4-ylamino)phenyl]methanone, used for the treatment of inflammatory diseases, allergic conditions, diabetes, obesity, metabolic syndrome, cognition disorder, cardiovascular and nervous system disorders | SCHERING CORPORATION (US) | 2011-02-01 | — | — | US | disclosed |
| US-7879880-B2 | such as [4-[(2-aminopyridin-4-yl)methyl]piperazin-1-yl]-[4-(pyridin-4-ylamino)phenyl]methanone, used for the treatment of inflammatory diseases, allergic conditions, diabetes, obesity, metabolic syndrome, cognition disorder, cardiovascular and nervous system disorders | SCHERING CORPORATION (US) | 2011-02-01 | — | — | US | disclosed |
| WO-2008146064-A1 | NEW BENZOFURAN DERIVATIVES AS SELECTIVE 5HT7 RECEPTOR INHIBITORS AND PROCESS FOR THEIR PREPARATION | EGIS GYÓGYSZERGYÁR (HU) | 2008-12-04 | — | — | WO | disclosed |
| US-20070142394-A1 | Substituted aniline derivatives useful as histamine H3 antagonists | SCHERING CORPORATION | 2007-06-21 | — | — | US | disclosed |
| US-20070142394-A1 | Substituted aniline derivatives useful as histamine H3 antagonists | SCHERING CORPORATION | 2007-06-21 | — | — | US | disclosed |
| US-4470989-A | Neuroleptic n-oxacyclyl-alkylpiperidine derivatives | HOECHST AKTIENGESELLSCHAFT (DE) | 1984-09-11 | — | — | US | disclosed |
| EP-0068261-A1 | N-oxacyclyl-alkylpiperidine derivatives, their preparation, pharmaceutical preparations containing them and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-01-05 | — | — | EP | disclosed |
| US-3989707-A | NEUROLEPTIC AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1976-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142394-A1 | Substituted aniline derivatives useful as histamine H3 antagonists | HRH3, CHRM2, HCRTR2 | ALDH1A1 2647/4885SMN1; SMN2 2370/4885OPRM1 28/4885 |
| US-20150225396-A1 | Quinazolinone Compounds and Derivatives Thereof | TNKS, TPI1, TNKS1BP1 | ALDH1A1 1715/4885SMN1; SMN2 3743/4885OPRM1 4436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.